大剂量阿糖胞苷治疗急性髓细胞白血病疗效及不良反应观察

The Outcome and Adverse Effect of High-dose Cytarabine in the Treatment of Acute Myeloid Leukemia

为探讨大剂量阿糖胞苷(Ara-c)用于急性髓细胞白血病(AML)完全缓解后巩固强化治疗的疗效及不良反应,本文分析5例AML患者,在治疗前完善细胞遗传学及分子生物学检查,经诱导治疗达到完全缓解(CR)后,即给予大剂量Ara-c(Ara-c 3g/m2,12小时1次,共6次)单药强化治疗共3疗程,每次化疗前均进行骨髓穿刺、分子生物学检查等判断治疗效果,观察15例次的治疗效果及不良反应。之后所有患者均持续完全缓解,并且早期达到分子生物学缓解,所有患者均出现明显的骨髓抑制及不同程度的感染、消化道反应等,但均安全度过,不影响进一步治疗。本研究提示大剂量Ara-c作为AML缓解后的巩固强化治疗方案,疗效确切、分子生物学缓解率高、安全性好。

This study discussed the outcome and adverse effects of high-dose cytarabine as consolidation therapy for patients with acute myeloid leukemia（AML） after complete remission. It concluded 5 patients with AML who completed the cytogenetics and molecular biology who were examined before chemotherapy. After induction therapy the patients achieved complete remission and received 3 courses of high-dose cytarabine （cytarabine 3g/m2, 12 hours once for 6 times） further. After the treatment, all the patients kept the complete remission and got molecular biology remission in the early stage of the chemotherapy. After high-dose cytarabine therapy, bone marrow suppression and infection, gastrointestinal reaction and so on were observed in all of them. While all the patients were safe, and recovered for the further treatment. The study showed that high-dose cytarabine as consolidation therapy for AML was effective with high molecular biology remission rate and also well tolerated.